Company Directory / biotechnology
PrivateFor profitbiotechnologyOxford, United Kingdom
Enara Bio
Ervaxx is illuminating the immune interface to develop new cancer therapies.
- Founded
- 2016 10 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $33M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
10 years old.
Reach
Website ranked #6,840,345 in the world for traffic, about 987 visits a month.
What it does
BiotechnologyHealth CareTherapeutics
Funding, as listed
$33M currency not stated
- Rounds2
- LatestSeries a, Nov 2019
- Investors2, 1 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Enara Bio, field by field. Contact details are held but never shown.
The company
- Name
- Enara Bio
- Type
- For profit
- Status
- Private
- Founded
- 2016
- Founders
- Drew Mark Pardoll, George Kassiotis, Houman Ashrafian
- Industry
- biotechnology
- Categories
- Biotechnology, Health Care, Therapeutics
Where
- City
- Oxford
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #6,840,345
- Monthly web visits
- 987
Funding, as listed
- Total
- 32,500,000 (currency not stated)
- Rounds
- 2
- Latest round
- Series a
- Latest round date
- Nov 2019
- Investors
- 2
- Lead investors
- 1
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Enara Bio may be growing as it has successfully licensed multiple Dark Antigens to Boehringer Ingelheim, indicating a significant business development and potential revenue stream. This licensing deal suggests that Enara Bio's proprietary technologies are being recognized and valued by larger pharmaceutical companies, which could lead to further commercial opportunities. The focus on developing off-the-shelf immunotherapies for non-small cell lung cancer, a major disease area, implies that Enara Bio is expanding its operational scope and targeting high-impact medical conditions.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.